| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 15 | 2025 | 128 | 6.520 |
Why?
|
| Epstein-Barr Virus Infections | 11 | 2024 | 292 | 3.320 |
Why?
|
| HIV Infections | 17 | 2026 | 2013 | 2.270 |
Why?
|
| Burkitt Lymphoma | 9 | 2024 | 132 | 2.160 |
Why?
|
| Herpesvirus 4, Human | 9 | 2024 | 641 | 2.090 |
Why?
|
| Malawi | 19 | 2026 | 336 | 1.580 |
Why?
|
| Herpesvirus 8, Human | 3 | 2023 | 47 | 1.550 |
Why?
|
| Lymphoma | 4 | 2023 | 328 | 1.470 |
Why?
|
| Histiocytosis, Langerhans-Cell | 5 | 2025 | 233 | 1.330 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2024 | 216 | 1.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2025 | 1312 | 1.170 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2023 | 163 | 1.150 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 157 | 1.140 |
Why?
|
| Child | 45 | 2026 | 26160 | 0.950 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2025 | 15 | 0.890 |
Why?
|
| Organ Transplantation | 2 | 2024 | 168 | 0.860 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 15 | 0.760 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2024 | 153 | 0.750 |
Why?
|
| Adolescent | 30 | 2026 | 20747 | 0.710 |
Why?
|
| Lymphoma, T-Cell | 4 | 2021 | 67 | 0.700 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 1275 | 0.650 |
Why?
|
| Interleukin-6 | 2 | 2019 | 412 | 0.630 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 279 | 0.620 |
Why?
|
| Anemia | 2 | 2023 | 351 | 0.600 |
Why?
|
| Viral Load | 4 | 2018 | 403 | 0.570 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2020 | 256 | 0.550 |
Why?
|
| Cytokines | 3 | 2021 | 1335 | 0.530 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 140 | 0.530 |
Why?
|
| Humans | 57 | 2026 | 130372 | 0.520 |
Why?
|
| Vincristine | 5 | 2020 | 189 | 0.480 |
Why?
|
| Child, Preschool | 19 | 2026 | 14984 | 0.460 |
Why?
|
| Neoplasms | 5 | 2026 | 2944 | 0.430 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 1796 | 0.400 |
Why?
|
| Lymphoma, B-Cell | 2 | 2025 | 146 | 0.380 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2025 | 1262 | 0.360 |
Why?
|
| Rituximab | 3 | 2024 | 170 | 0.360 |
Why?
|
| Male | 30 | 2026 | 64517 | 0.360 |
Why?
|
| Methotrexate | 3 | 2025 | 337 | 0.360 |
Why?
|
| Infant | 12 | 2026 | 13269 | 0.330 |
Why?
|
| Female | 30 | 2026 | 70274 | 0.330 |
Why?
|
| Hydroa Vacciniforme | 1 | 2010 | 3 | 0.330 |
Why?
|
| Hodgkin Disease | 3 | 2026 | 307 | 0.320 |
Why?
|
| Young Adult | 13 | 2025 | 9989 | 0.300 |
Why?
|
| Retrospective Studies | 11 | 2026 | 17606 | 0.300 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2020 | 134 | 0.300 |
Why?
|
| Disease Management | 2 | 2025 | 559 | 0.300 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2025 | 219 | 0.290 |
Why?
|
| Tanzania | 3 | 2023 | 67 | 0.270 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 510 | 0.270 |
Why?
|
| Prognosis | 6 | 2025 | 4893 | 0.260 |
Why?
|
| Bone Marrow | 3 | 2021 | 319 | 0.250 |
Why?
|
| Recurrence | 3 | 2025 | 1481 | 0.250 |
Why?
|
| Anti-Retroviral Agents | 2 | 2026 | 153 | 0.240 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1300 | 0.240 |
Why?
|
| Prospective Studies | 8 | 2025 | 6421 | 0.240 |
Why?
|
| Reed-Sternberg Cells | 1 | 2026 | 19 | 0.240 |
Why?
|
| Immunotherapy | 4 | 2022 | 753 | 0.240 |
Why?
|
| Survival Rate | 5 | 2025 | 2131 | 0.230 |
Why?
|
| Laboratories, Hospital | 1 | 2025 | 24 | 0.230 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 899 | 0.220 |
Why?
|
| Cellular Senescence | 1 | 2026 | 217 | 0.210 |
Why?
|
| Doxorubicin | 3 | 2020 | 289 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2025 | 355 | 0.200 |
Why?
|
| Cell Differentiation | 2 | 2026 | 1929 | 0.200 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 889 | 0.200 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2025 | 189 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 168 | 0.200 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2023 | 3 | 0.200 |
Why?
|
| Adult | 10 | 2025 | 31117 | 0.200 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 436 | 0.200 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 13 | 0.190 |
Why?
|
| Treatment Outcome | 11 | 2025 | 12855 | 0.190 |
Why?
|
| HIV-1 | 2 | 2016 | 480 | 0.190 |
Why?
|
| Mucositis | 1 | 2022 | 20 | 0.190 |
Why?
|
| Morbidity | 1 | 2023 | 259 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 305 | 0.180 |
Why?
|
| Haploinsufficiency | 1 | 2024 | 263 | 0.180 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5185 | 0.180 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 121 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 379 | 0.180 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 348 | 0.180 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 289 | 0.180 |
Why?
|
| Perforin | 1 | 2021 | 24 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2023 | 240 | 0.170 |
Why?
|
| Virus Replication | 1 | 2023 | 597 | 0.160 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 342 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 197 | 0.160 |
Why?
|
| Cysticercosis | 1 | 2020 | 21 | 0.160 |
Why?
|
| Bleomycin | 2 | 2020 | 118 | 0.160 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2020 | 60 | 0.150 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 32 | 0.150 |
Why?
|
| Anthracyclines | 2 | 2017 | 42 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 614 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 312 | 0.140 |
Why?
|
| Endemic Diseases | 1 | 2018 | 59 | 0.140 |
Why?
|
| HIV Protease Inhibitors | 1 | 2018 | 44 | 0.140 |
Why?
|
| Virus Activation | 1 | 2018 | 85 | 0.140 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 347 | 0.130 |
Why?
|
| Biopsy | 1 | 2021 | 1237 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2017 | 76 | 0.130 |
Why?
|
| Asia | 1 | 2017 | 125 | 0.130 |
Why?
|
| Risk Factors | 5 | 2026 | 10937 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 103 | 0.120 |
Why?
|
| Europe | 1 | 2017 | 366 | 0.120 |
Why?
|
| HIV | 1 | 2017 | 177 | 0.120 |
Why?
|
| Risk | 1 | 2017 | 729 | 0.120 |
Why?
|
| Remission Induction | 1 | 2016 | 300 | 0.110 |
Why?
|
| Developing Countries | 1 | 2017 | 302 | 0.110 |
Why?
|
| Angiomatosis, Bacillary | 1 | 2014 | 3 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3800 | 0.110 |
Why?
|
| Algorithms | 1 | 2021 | 1679 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2018 | 1451 | 0.100 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 1711 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 362 | 0.100 |
Why?
|
| Child Health Services | 1 | 2013 | 87 | 0.090 |
Why?
|
| Biomarkers | 1 | 2021 | 3393 | 0.090 |
Why?
|
| Adenoviridae Infections | 1 | 2011 | 76 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 226 | 0.080 |
Why?
|
| Proteomics | 1 | 2014 | 610 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 3425 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2025 | 8493 | 0.080 |
Why?
|
| DNA, Viral | 3 | 2017 | 452 | 0.080 |
Why?
|
| United States | 2 | 2023 | 11819 | 0.070 |
Why?
|
| Genomics | 1 | 2017 | 1619 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1125 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1889 | 0.070 |
Why?
|
| Transcriptome | 1 | 2014 | 1130 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 6131 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2478 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2018 | 228 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 850 | 0.060 |
Why?
|
| Prednisone | 2 | 2019 | 238 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 3720 | 0.060 |
Why?
|
| Time Factors | 1 | 2016 | 6186 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2026 | 1829 | 0.060 |
Why?
|
| Incidence | 2 | 2026 | 3328 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2017 | 4675 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 900 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 2019 | 360 | 0.050 |
Why?
|
| Adenine Nucleotides | 1 | 2024 | 37 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2025 | 351 | 0.050 |
Why?
|
| Arabinonucleosides | 1 | 2024 | 34 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 78 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 96 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2024 | 190 | 0.050 |
Why?
|
| Middle Aged | 5 | 2025 | 28370 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2024 | 174 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1606 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2024 | 234 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 261 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2025 | 288 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 165 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2022 | 233 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2022 | 325 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 397 | 0.040 |
Why?
|
| Anticestodal Agents | 1 | 2020 | 2 | 0.040 |
Why?
|
| Chromatin | 1 | 2024 | 504 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 179 | 0.040 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 15 | 0.040 |
Why?
|
| Praziquantel | 1 | 2020 | 13 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 175 | 0.040 |
Why?
|
| Taenia solium | 1 | 2020 | 13 | 0.040 |
Why?
|
| Albendazole | 1 | 2020 | 26 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 130 | 0.040 |
Why?
|
| Apoptosis | 1 | 2026 | 1843 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 217 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2026 | 2026 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 312 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 1229 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 823 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2017 | 37 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1164 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 126 | 0.030 |
Why?
|
| Viremia | 1 | 2016 | 131 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 489 | 0.030 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 60 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 44 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2016 | 3680 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1100 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2024 | 2457 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 235 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1399 | 0.020 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 188 | 0.020 |
Why?
|
| Child Nutrition Disorders | 1 | 2013 | 41 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 214 | 0.020 |
Why?
|
| Botswana | 1 | 2013 | 74 | 0.020 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 1494 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1484 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1334 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 694 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 93 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 1797 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 693 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 220 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 33924 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 499 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 166 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 669 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 220 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2835 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 502 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1076 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 982 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 752 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 509 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 767 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 1458 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7381 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1232 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 18213 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 1231 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1608 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 682 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 20883 | 0.010 |
Why?
|